Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection

Next Previous
Trial Profile

A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Murepavadin (Primary)
  • Indications Pseudomonal infections; Ventilator associated pneumonia
  • Focus Pharmacokinetics
  • Sponsors Polyphor

    • Most Recent Events

    • 26 Apr 2021 This trial has been discontinued in Spain (End Date: 02 Dec 2015), according to European Clinical Trials Database record.
    • 25 Apr 2017 Results assessing PK and efficacy, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 12 Apr 2016 Interim results (n=10) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top